Espindolol - PsiOxus Therapeutics

Drug Profile

Espindolol - PsiOxus Therapeutics

Alternative Names: MT-102; S-pindolol

Latest Information Update: 20 Aug 2015

Price : $50

At a glance

  • Originator PsiOxus Therapeutics
  • Class Irritable bowel syndrome therapies; Small molecules
  • Mechanism of Action Beta-adrenergic receptor agonists; Beta-adrenergic receptor antagonists; Serotonin 1A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Cachexia
  • Preclinical Muscular atrophy

Most Recent Events

  • 20 Aug 2015 Phase II development for Cachexia is ongoing
  • 12 Nov 2013 Final efficacy data from a phase II trial in Cachexia released by PsiOxus Therapeutics
  • 31 May 2013 PsiOxus Therapeutics completes a phase II trial in Cachexia in Belgium, Germany, India, Malaysia, Spain and the United Kingdom (ACT1; NCT01238107; EudraCT2010-022486-10)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top